These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Efficacy and tolerability of once-weekly administration of 35 mg alendronate and 17.5 mg risedronate]. Kishimoto H Nihon Rinsho; 2007 Nov; 65 Suppl 9():365-8. PubMed ID: 18161133 [No Abstract] [Full Text] [Related]
3. New bisphosphonates and trends in drug therapy for osteoporosis: preface. Matsumoto T Clin Calcium; 2009 Jan; 19(1):9. PubMed ID: 19170268 [No Abstract] [Full Text] [Related]
5. Going on a drug holiday? Bonnick SL J Clin Densitom; 2011; 14(4):377-83. PubMed ID: 22051091 [No Abstract] [Full Text] [Related]
6. [Postmenopausal osteoporosis. Bisphosphonates are not all equal]. MMW Fortschr Med; 2009 Mar; 151(11):46-7. PubMed ID: 19469206 [No Abstract] [Full Text] [Related]
7. Bisphosphonates. A cornerstone of osteoporosis treatment. Mayo Clin Womens Healthsource; 2007 May; 11(5):1-2. PubMed ID: 17476171 [No Abstract] [Full Text] [Related]
8. Adverse events and intravenous versus oral bisphosphonate use in patients with osteoporosis and cancer in the U.S. Skrepnek GH; Seal B; Tangirala M; Jeffcoat MK; Watts NB; Hay JW Gen Dent; 2010; 58(6):484-92; quiz 493-4. PubMed ID: 21062718 [TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates and atypical femoral fractures: a time for reflection. Compston JE Maturitas; 2010 Jan; 65(1):3-4. PubMed ID: 19932574 [No Abstract] [Full Text] [Related]
10. Yearly zoledronic acid in postmenopausal osteoporosis. Karam R; Camm J; McClung M N Engl J Med; 2007 Aug; 357(7):712-3; author reply 714-5. PubMed ID: 17703529 [No Abstract] [Full Text] [Related]
11. [Diphosphonate therapy and osteonecrosis of the jaw]. Løkken P; Skoglund LA; Skjelbred P Tidsskr Nor Laegeforen; 2007 Aug; 127(15):1945-7. PubMed ID: 17700737 [No Abstract] [Full Text] [Related]
12. Pharmacovigilance of oral bisphosphonates: adverse effects manifesting in the soft tissue of the oral cavity. Kharazmi M; Persson U; Warfvinge G J Oral Maxillofac Surg; 2012 Dec; 70(12):2793-7. PubMed ID: 22609135 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis. Iwamoto J; Takeda T; Sato Y Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313 [TBL] [Abstract][Full Text] [Related]
15. [Treatment with bisphosphonates and previous dental health]. Madrid C; Bouferrache K; Jaques B; Broome M Rev Med Suisse; 2009 Apr; 5(200):909-10; author reply 910-1. PubMed ID: 19438092 [No Abstract] [Full Text] [Related]
16. Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease. Bobba RS; Beattie K; Parkinson B; Kumbhare D; Adachi JD Drug Saf; 2006; 29(12):1133-52. PubMed ID: 17147460 [TBL] [Abstract][Full Text] [Related]
18. Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention. Bock O; Boerst H; Thomasius FE; Degner C; Stephan-Oelkers M; Valentine SM; Felsenberg D J Musculoskelet Neuronal Interact; 2007; 7(2):144-8. PubMed ID: 17627083 [TBL] [Abstract][Full Text] [Related]
19. Osteochemonecrosis of jaws and bisphosphonates. Khosa AD; Nayyar MS; Beirne JC Ir Med J; 2007 Mar; 100(3):410-1. PubMed ID: 17491545 [TBL] [Abstract][Full Text] [Related]
20. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws. Kunchur R; Need A; Hughes T; Goss A J Oral Maxillofac Surg; 2009 Jun; 67(6):1167-73. PubMed ID: 19446200 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]